Synthesis, 68Ga-Radiolabeling, and Preliminary In Vivo Assessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent

<div>Images of BALB/c mice acquired using a Triumph μPET/CT preclinical imaging system (GE Healthcare, Buckinghamshire, United Kingdom). (a) Representative μPET/CT images acquired at 25 min after 68Ga-DOTA-TBIA101 administration, (A) maximum intensity projection (MIP) image of a healthy animal demonstrating renal excretion, (B) pelvis projection including the muscular infection site (MIS) located in the right hind muscle tissue. The arrows indicate 68Ga-DOTA-TBIA101 activity uptake at the site of infection. No activity uptake was noted in the contralateral muscle tissue. (b) Three-dimensional μPET images show activity uptake at the infection site (indicated by the white arrows) in (C) coronal, (D) sagittal, and (E) axial orientation. Ki is Kidney and Bl is Bladder.</div>

BioMed Research International

fig4

Figure 4

Figure 4: Synthesis, 68Ga-Radiolabeling, and Preliminary In Vivo Assessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent

Figure 4 | Synthesis, 68Ga-Radiolabeling, and Preliminary In Vivo Assessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent 